Efficacy and safety of sintilimab plus bevacizumab and CAPOX as first-line treatment for patients with RAS-mutant, microsatellite stable, metastatic colorectal cancer

Efficacy and safety of sintilimab plus bevacizumab and CAPOX as first-line treatment for patients with RAS-mutant, microsatellite stable, metastatic colorectal cancer

Abstract Background This research aimed to assess the efficacy and safety of combining sintilimab with bevacizumab, oxaliplatin, and capecitabine as a primary therapy for patients with RAS-mutated, microsatellite stable (MSS), and metastatic colorectal cancer (mCRC). Methods In this prospective, ope...

Full description

Saved in:
Bibliographic Details
Main Authors: Yanrong Wang, Ru Jia, Haiyan Si, Yue Ma, Mengjiao Fan, Nan Zhang, Fangfang Liu, Yue Shi, Yushan Jia, Yaoyue Zhang, Quanli Han, Zhikuan Wang, Guanghai Dai
Format: Article
Language:English
Published: BMC 2025-03-01
Series:BMC Cancer
Subjects:
Microsatellite stable
Immune checkpoint inhibitor
Anti-angiogenesis
Metastatic colorectal cancer
Liver metastases
Online Access:https://doi.org/10.1186/s12885-025-13794-w
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12885-025-13794-w

Similar Items